It Takes Two: GE Healthcare and SHINE team up to solve longstanding radiopharmaceutical supply concerns in medical imaging

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

CHALFONT ST. GILES, UK – 9 November 2015 – Technetium-99m (Tc‑99m) is used in more than 40 million medical imaging procedures each year, primarily stress tests to assess heart disease, and bone scans to determine the stage of cancer progression. This essential medical isotope is generated in pharmacies and hospitals from another isotope—molybdenum-99 (Mo-99).  Despite using half of the world’s supply of Mo‑99, the United States does not produce any domestically and imports 100 percent of its supply from foreign nuclear reactors.